Clinical Trials Browser

Tyrosine Kinase Inhibitors × Clear all

NCT03817398 2026-04-13

Stopping Tyrosine Kinase Inhibitors in Affecting Treatment-Free Remission in Patients With Chronic Phase Chronic Myeloid Leukemia

Phase 2 Active not recruiting

Other hematologic neoplasm

Leukemia, Myeloid, Chronic-Phase

NCT05494580 2026-03-10

Pamiparib Plus Surufatinib in Patients With Platinum-resistant Ovarian Cancer

Phase 1/2 Completed

Ovarian Neoplasms

NCT05824468 2026-03-10

Zimberelimab Plus Lenvatinib After Progression on Prior Immune Checkpoint Inhibitors for Advanced Cervical Cancer

Phase 2 Active not recruiting

Uterine Cervical Neoplasms

NCT05824481 2026-03-10

Study of Cadonilimab (AK104) Plus Lenvatinib in Patients With Advanced Endometrial Cancer

Phase 2 Active not recruiting

Endometrial Neoplasms

NCT04318938 2026-03-02

Advancing Brigatinib Properties in ALK+ NSCLC Patients by Deep Phenotyping

Phase 2 Active not recruiting

NSCLC

NCT07413263 2026-02-18

Impact of Tyrosine Kinase Inhibitors on Glucose Level and Lipid Metabolism in Chronic Myeloid Leukemia Patients

Not yet recruiting

MyeloidOther hematologic neoplasm

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT03611738 2026-02-09

Ceritinib Plus Docetaxel in ALK-Negative, EGFR WT Advanced NSCLC

Phase 1 Active not recruiting

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT04777994 2025-12-23

Study With ABBV-CLS-484 in Participants With Locally Advanced or Metastatic Tumors

Phase 1 Recruiting

GenitourinaryHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Neoplasms, Recurrence

NCT03963544 2025-12-10

METAGIST

492 enrolled 7 charts

Gastro Intestinal Stromal Tumor

NCT04151342 2025-12-03

CARMA-BROS

Congenital Abnormalities, Neoplasms, Neoplasms, Second Primary

NCT07219459 2025-10-21

GDFATHERHCC01

Phase 2 Not yet recruiting

Gastrointestinal

Carcinoma, Hepatocellular

NCT05236946 2025-09-10

Observation or Upfront Cranial RT in Oncogene Mutated NSCLC With Asymptomatic BM: A Phase III RCT

Phase 3 Recruiting

Asymptomatic Brain Metastases

NCT04440267 2025-08-06

Efficacy of Acute Lymphoblastic Leukemia-Based Therapy in Treating Patients With Acute Leukemia of Ambiguous Lineage

Phase 2 Recruiting

Other hematologic neoplasm

Leukemia, Biphenotypic, Acute

NCT04508725 2025-07-25

Serial Ultrasound in Metastatic Renal Cell Carcinoma (mRCC)

Phase NA Completed

22 enrolled 16 charts

Carcinoma, Renal Cell, Kidney Neoplasms

NCT03958565 2025-05-21

Response of Bony Metastasis to Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancers With Actionable Driver Mutations.

Carcinoma, Non-Small-Cell Lung

NCT06858956 2025-03-05

Real-World Study of Chidamide Combined With PD-(L)1 Inhibitors and Anti-Angiogenic Therapy for Advanced MSS-Type Colorectal Cancer

Not yet recruiting

Gastrointestinal

Colorectal Neoplasms

NCT03314740 2025-01-10

BAROCCO

Phase 2 Completed

123 enrolled 14 charts

Ovarian Neoplasms

NCT06682247 2024-11-12

A Real-world Study of Chidamide in Combination with PD-1/PD-L1 Antibodies and Anti-angiogenic Agents in Advanced MSS Colorectal Cancer

Not yet recruiting

Gastrointestinal

Colorectal Cancer Metastatic

NCT06632106 2024-10-08

HAIC in Combination with Immune Checkpoint Inhibitors and Tyrosine Kinase Inhibitors for Advanced HCC

Active not recruiting

Gastrointestinal

Carcinoma, Hepatocellular

NCT04375150 2024-09-19

Master Protocol to Study Treatment Patterns, Medication Adherence, Health and Economic Outcomes and Unmet Needs in RCC

355 enrolled 23 charts

Carcinoma, Renal Cell

NCT02949843 2024-06-28

Targeted Therapy in Treating Patients With Incurable Non-Small Cell Lung Cancer With Genetic Mutations

Phase 2 Terminated

19 enrolled 16 charts

Carcinoma, Non-Small-Cell Lung

NCT06232759 2024-06-10

TACE Combined With Tyrosine Kinase Inhibitors and Tislelizumab in Unresectable Hepatocellular Carcinoma

Phase 2 Completed

Gastrointestinal

Carcinoma, Hepatocellular

NCT03890731 2024-04-02

A Clinical Study of Regorafenib in Participants Who Have Been Treated in Previous Bayer-sponsored Regorafenib Studies That Have Been Completed

Phase 2 Completed

6 enrolled 11 charts

GastrointestinalGenitourinary

Carcinoma, Renal Cell, Carcinoma, Hepatocellular, Colorectal Neoplasms

NCT03256981 2023-12-26

HALT

Phase 2/3 Unknown

NSCLC

NCT06121765 2023-11-08

Metabolic Alternation and Clinicohematological Characteristic in Chronic Phase CML in Patient Treated With TKI

Other hematologic neoplasm

Leukemia, Myeloid, Chronic-Phase

NCT06059885 2023-09-29

Tislelizumab Plus TKI as Adjuvant Therapy Versus Active Surveillance in Patients With HCC

Phase 2 Unknown

Gastrointestinal

Liver Neoplasms

NCT01859026 2023-01-19

A Phase I/IB Trial of MEK162 in Combination With Erlotinib in NSCLC Harboring KRAS or EGFR Mutation

Phase 1 Completed

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT05476562 2022-11-08

Study Conducted Among Patients With CML

MyeloidOther hematologic neoplasm

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT04006847 2022-07-01

Omega -3 Fatty Acid in Combination With Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia

Phase 1/2 Terminated

1 enrolled 5 charts

Other hematologic neoplasm

Leukemia, Myeloid, Chronic-Phase

NCT05422183 2022-06-16

Envafolimab, Lenvatinib Combined With VP-16 in Platinum-resistant Recurrent Epithelial Ovarian Cancer

Phase 2 Unknown

Carcinoma, Ovarian Epithelial

NCT02794337 2022-04-27

TACE-SBRT

Phase 2/3 Unknown

Gastrointestinal

Carcinoma, Hepatocellular

NCT01649180 2021-08-12

PrE0801

Phase 2 Terminated

3 enrolled 7 charts

Carcinoma, Renal Cell, Kidney Neoplasms

NCT04760431 2021-06-02

TKIs vs. Pertuzumab in HER2+ Breast Cancer Patients With Active Brain Metastases (HER2BRAIN)

Phase 2 Unknown

Brain Neoplasms

NCT01999985 2020-11-27

Phase I Trial of Afatinib (BIBW 2992) and Dasatinib in Non-small Cell Lung Cancer (NSCLC)

Phase 1 Completed

25 enrolled 10 charts

Carcinoma, Bronchogenic, Carcinoma, Non-Small-Cell Lung, Lung Diseases, Lung Neoplasms, Neoplasms, Neoplasms by Site, Pleural Diseases, Pleural Effusion, Pleural Neoplasms, Respiratory Tract Diseases, Respiratory Tract Neoplasms, Thoracic Neoplasms, Pleural Effusion, Malignant

NCT01460498 2020-03-05

Azacitidine (AZA) in Minimal Residual Disease (MRD) Chronic Myeloid Leukemia (CML)

Phase 1 Completed

MyeloidOther hematologic neoplasm

Leukemia, Philadelphia Chromosome, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Neoplasm, Residual

NCT03799094 2019-01-10

Vitamin C and Tyrosine Kinase Inhibitor in Lung Cancer Patients With Epidermal Growth Factor Receptor Mutations

Phase 1/2 Unknown

Carcinoma, Non-Small-Cell Lung

NCT02730195 2019-01-09

Pioglitazone and Tyrosine Kinase Inhibitor in Treating Patients With Relapsed Chronic Myeloid Leukemia

Phase 2 Terminated

9 enrolled 8 charts

MyeloidOther hematologic neoplasm

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT03624530 2018-08-10

Effect of Prophylactic TKI Therapy Post-transplants on Ph+ ALL Undergoing Allo-HSCT With MRD Positive Pre-transplants

Phase 2/3 Unknown

Neoplasm, Residual

NCT03424980 2018-02-08

A Study to Evaluate Effectiveness and Safety of Tyrosine Kinase Inhibitors

Brain Neoplasms, Carcinoma, Non-Small-Cell Lung

NCT01098500 2017-05-30

Liver Function Test (LFT) Elevations in Cancer Patients and Users of Tyrosine Kinase Inhibitor (TKI) Drugs

3,800 enrolled 19 charts

Neoplasms

NCT02906163 2016-09-19

First Line Bio-immunotherapy With Thymosin Alpha 1 in Patients With Sensitizing EGFR Mutation Positive Non Small Cell Lung Cancer Who Are Taking Standard of Care Therapy

Phase 1/2 Unknown

Carcinoma, Non-Small-Cell Lung

NCT02687425 2016-02-22

SESPI

Phase 2 Unknown

MyeloidOther hematologic neoplasm

Leukemia, Myelogenous, Chronic, BCR-ABL Positive